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Abstract
Human bocavirus (HBoV) was recently described as a new member of the Parvoviridae. In order to investigate the suggested association
of HBoV with respiratory and gastric disease in infants and young children, sera of 357 paediatric patients hospitalized with infectious
and non-infectious diseases were retrospectively analyzed for the presence of HBoV DNA and virus-speciﬁc antibodies using quantita-
tive PCR and ELISA, respectively. HBoV seroprevalence was determined to range from 25% in infants younger than 1 year of age to
93% in children aged more than 3 years. Viral loads between 1 · 102 and 1.2 · 106 geq/mL were observed in 6.7% (20/297) of sera
obtained preferentially from young children suffering from infectious diseases. HBoV genomes were furthermore detected in 5% (3/60)
of sera collected from individuals with non-infectious illnesses. HBoV DNA was present most frequently in patients with respiratory
disease (9.6%). Whereas only 5.2% of patients with upper respiratory tract disease were viraemic, HBoV DNA was found in 14.6%
and 10.0% of patients with lower respiratory tract illness and pneumonia, respectively. Acute HBoV infections were also observed in
7.5% of patients with gastroenteritis and in one child with inﬂammatory bowel disease. None of 77 patients hospitalized for various
other infectious diseases (e.g. rash, urinary tract infection, meningitis) displayed viraemia. In 60.9% and 47.8% of DNA-positive children,
HBoV-speciﬁc IgM and IgG was observed, respectively. The present prospective study provides comprehensive data on the clinical
association of acute HBoV infection with respiratory illness and on the seroprevalence of virus-speciﬁc antibodies in children.
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Introduction
Human bocavirus (HBoV), a recently discovered member of
the Parvoviridae, was identiﬁed in children with respiratory
infections [1,2]. Phylogenetic analysis of the viral genome has
revealed a close relationship of HBoV to the canine minute
virus and bovine parvovirus, which are both members of the
genus Bocavirus. Several HBoV isolates with high sequence
homology have been described [3]. HBoV was detected using
PCR-based techniques not only in clinical respiratory sam-
ples, but also in faecal excretions of young children in
Australia, North America, Asia, Europe, Africa and the
Middle East, indicating a worldwide distribution of the virus
[4–19]. The prevalence of HBoV-DNA in samples of children
with respiratory illness is in the range 1.5–18.3% and may
vary depending on seasonal ﬂuctuations and the age of the
patients. In children, HBoV tends to be linked with a high
rate of co-infections with other respiratory viruses (e.g.
picornaviruses, adenoviruses, respiratory syncytial virus and
human metapneumovirus) [20]. HBoV has been estimated to
be the fourth most prevalent single virus after respiratory
syncytial virus (RSV), rhino- and adenovirus in children hospi-
talized with respiratory disease [21]. Because most studies
did not include control samples from children without symp-
toms indicating the involvement of infections, HBoV has not
been clearly identiﬁed as a pathogen responsible for respira-
tory diseases.
Studies of the seroprevalence of HBoV have described the
use of recombinant VP1 and VP2 proteins and VP2 virus-like
particles (VP2–VLP) for the detection of HBoV-speciﬁc IgG
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in Japanese, Chinese, Finnish and German populations
[22–25]. Thereby, ubiquitous antibody responses with a sero-
prevalence of up to 94–100% were detected in adults and
in children aged more than 6 years, whereas seronegative
individuals were predominantly found among small children
aged approximately 1–2 years.
In the present study, we present a comprehensive over-
view concerning the frequency and impact of acute HBoV
infection in 297 children and adolescents hospitalized with
symptoms indicating the involvement of infectious diseases.
In addition, sera derived from 60 children were included
who were admitted because of various non-infectious condi-
tions (e.g. planned surgery, bone fractures, accidents).
Materials and Methods
Patients and controls
Between December 2006 and May 2007, sera were collected
from 297 patients (160 males, 137 females, age range 1–
190 months, mean age 57.4 months) at the Children’s
Hospital St Hedwig (University of Regensburg). All samples
were derived from immunocompetent caucasians with resi-
dence in Bavaria (Germany), who were hospitalized with
characteristic symptoms and clinical parameters of infectious
diseases (i.e. fever, elevated C-reactive protein, leukocytosis).
Follow-up samples were available from six children. Sixty
children (38 males, 22 females, age range 1–194 months,
mean age 77.9 months) with non-infectious conditions (i.e.
planned surgery, accidents, fractures) served as controls.
Detection of HBoV DNA and HBoV-speciﬁc antibodies
The HBoV DNA was isolated from serum using the QiaAmp
DNA blood mini kit (Qiagen, Hilden, Germany) and ampli-
ﬁed using real-time TaqMan PCR, as described previously
[22,26]. For the detection of HBoV-speciﬁc antibodies, an
ELISA based on recombinant HBoV VP2–VLP was used
[22,26].
Laboratory analysis of infectious diseases
All patients were routinely tested for blood parameters
indicative for infectious diseases and inﬂammatory processes
(e.g. C-reactive protein, differential blood cell count).
Depending upon the disease manifestation, throat swabs/
respiratory aspirates and stool samples from patients with
respiratory and gastrointestinal symptoms, respectively, were
routinely analyzed using bacterial culture techniques; all sam-
ples from patients with respiratory symptoms were tested
for the presence of RSV using routine antigen detection sys-
tems. Samples testing negative for bacterial pathogens were
additionally analyzed for the presence of respiratory (inﬂu-
enza-, human metapneumo-, adenovirus) or gastrointestinal
viruses (rota-, noro-, enterovirus) using PCR and/or routine
antigen detection systems. In special cases, assays for the
detection of further viral pathogens (e.g. Epstein–Barr and
human cytomegalovirus) were performed.
Ethics
The study was approved by the ethics committee of the
University of Regensburg (no. 06/85). Only sera drawn for
diagnostic and/or clinical reasons were included in the study.
Parental consent was obtained prior to sample processing.
Statistical data analysis
All data were evaluated by chi squared and the Mann–
Whitney U-test for independent samples.
Results
Description of patients included in the study
A total of 297 children and adolescents with symptoms indi-
cating infectious diseases were studied. With respect to their
clinical diagnosis, the children were divided into three groups
(Table 1). Group A comprised 156/297 patients (52.5%) with
diseases of the respiratory tract, who were subdivided into
58 patients with symptoms involving the upper respiratory
tract (i.e. rhinitis, otitis media, laryngitis, tonsillitis, cough), 48
patients with symptoms involving the lower respiratory tract
(i.e. wheezing bronchitis and bronchiolitis) and 50 patients
with pneumonia. The diagnosis of pneumonia was routinely
conﬁrmed by X-ray analysis. Of the 297 patients, 64 (21.5%,
group B) presented with gastrointestinal symptoms (i.e. diar-
rhoea, nausea, vomiting). Eleven of them were diagnosed
with chronic inﬂammatory bowel disease. The third patient
group (group C) comprised 77 patients (77/297, 25.9%) with
a broad range of infections involving neither the respiratory
nor the gastrointestinal tract (e.g. meningitis, encephalitis and
urinary tract infections). Furthermore, 60 children without
infectious diseases were included in the study. Because respi-
ratory aspirates were available only from a small subgroup of
patients, analysis was focused on sera that were drawn dur-
ing hospitalization and tested for the presence of HBoV-spe-
ciﬁc humoral immune reactions and viral DNA.
Age-related prevalence of HBoV DNA and of HBoV-speciﬁc
antibodies
A seroprevalence of 71.4% (255/357 patients) was observed
ranging from 23% at the age of 7–9 months to more than
90% in children aged 31–36 months or more (Fig. 1A).
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Gender-speciﬁc differences were not evident. A reduction of
seroprevalence from 78% to 23% was observed in children
up to the age of 7–9 months. In parallel, the median IgG
titres declined from 741 relative units (RU) to 65 RU
(Fig. 1B). Because acute HBoV infections were only occasion-
ally observed in these age groups (Fig. 1C), the detected IgG
mainly represent maternal antibodies. Starting at the age of
25 months, rising values of both seroprevalence and IgG-
titres were observed as a consequence of the accumulating
numbers of acute HBoV infections occurring in children aged
13–30 months (Fig. 1A,C).
HBoV genomes were observed preferentially in sera from
patients aged younger than 30 months. In older patients, only
sporadic HBoV-infections were observed (Fig. 1C). Whereas
the mean age of all patients was 67.7 months, patients with
acute HBoV infection had a lower mean age of 24.9 months
(Table 2).
Viral genomes and HBoV-speciﬁc antibodies in patients
and controls
HBoV DNA indicating acute infection were detected in 20/
297 patients (6.7%) and three 60 controls (5.0%) (Table 1).
Although these overall values were rather similar, differ-
ences became evident after correlating patient groups A, B
and C with markers for acute HBoV infection: in the serum
samples derived from 15/156 (9.6%) patients of group A
(patients 1–15) presenting with symptoms of respiratory
tract disease, HBoV DNA was detectable at concentrations
varying between 102 and 103 and 1.2 · 106 geq/mL (Tables 1
and 3). Follow-up samples were available for patient 10,
comprising a girl suffering from bronchitis. The reduction in
the DNA load from 1.9 · 105 to 4.6 · 103 geq/mL within
3 days was observed in combination with increasing amounts
of VP2-speciﬁc IgM (Table 3). The prevalence of HBoV
DNA in serum was highest in children suffering from dis-
eases of the lower respiratory tract (7/48, 14.6%) and from
pneumonia (5/50, 10.0%) compared to upper respiratory
tract disease (3/58, 5.2%) (Table 1). With respect to patients
of group C (other infections, 0/77) and those with non-
infectious diseases (3/60, 5.0%), the frequency of acute
HBoV infection was signiﬁcantly elevated in patients with
lower respiratory tract disease and pneumonia (Table 4).
Co-infections with other pathogens were observed in
patients 4 (RSV) and 12 (streptococcus A). Low-level HBoV
viraemia (1 · 102–3.3 · 103 geq/mL) was also observed in 5/
64 patients (7.8%) with gastroenteritis, one of whom was
diagnosed as having chronic inﬂammatory bowel disease. In
patients 16–18 with gastroenteritis, rotavirus infection was
diagnosed in addition.
With the exception of patients with lower respiratory
tract disease, the mean age of the HBoV DNA-positive
patients was lower compared to that of all patients of the
respective groups (Table 2). This tendency was most evident
in children with gastroenteritis (group B) with a mean age of
58.4 months for all patients and 15.5 months for HBoV-
infected patients. Although young children preferentially pre-
sented with gastroenteritis or respiratory tract symptoms,
particularly pneumonia was the lead diagnosis in children
infected at an age of 22 months or more.
In children with non-infectious condition, HBoV DNA was
detectable in three patients: one newborn boy (patient 21)
suffering from haematemesis, one girl (patient 22) presenting
with atonic seizures and a boy with a submandibular gland
abscess (patient 23). Respiratory or gastrointestinal symptoms
that possibly manifested during the preceding weeks were not
reported.










IgG VP2 HBoV DNA
Infectious disease 297 57.4 1–190 209/297 70.3% 20/297 6.7%
(A) Respiratory tract 156 40.5 1–178 95/156 60.9% 15/156 9.6%
Upper respiratory tract
(rhinitis, otitis media, laryngitis,
tonsillitis)
58 48.3 1–178 36/58 62.1% 3/58 5.2%
Lower respiratory tract (wheezing
bronchitis, broncheolitis)
48 20.1 1–95 24/48 50.0% 7/48 14.6%
Pneumonia 50 51.8 5–167 35/50 70.0% 5/50 10.0%
(B) Gastrointestinal tract 64 68.5 1–173 49/64 76.6% 5/64 7.8%
Diarrhoea, nausea, vomiting 53 58.4 1–161 38/53 71.7% 4/53 7.5%
Chronic inﬂammatory bowel disease 11 117.5 41–173 11/11 100.0% 1/11 9.1%
(C) Others (febrile convulsion urinary
tract infection, exanthema, meningitis,
encephalitis)
77 82.7 4–190 65/77 84.4% 0/77 0.0%
Non-infectious condition (e.g. bone
fracture, planned surgery)
60 77.9 1–194 44/60 73.3% 3/60 5.0%
Total 357 67.7 1–194 255/357 71.4% 23/357 6.4%
The number of patients in which speciﬁc antibodies or viral DNA could be detected is shown for each subgroup.
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HBoV-speciﬁc antibodies
IgG against HBoV VP2–VLP were detected in all patient
groups, irrespective of the disease pattern. Overall, 255/357
children were IgG-positive: 209/297 (70.3%) of patients with
infections and 44/60 (73.3%) of patients with non-infectious
diseases (Table 1). The seroprevalence ranged from 50% in
patients with lower respiratory tract disease to 84.4% in
patient group C.
The majority of HBoV DNA-positive patients (14/23,
60.7%) produced virus-speciﬁc IgM as an additional marker
for acute infection: 9/23 patients (39.1%; patients 3, 7, 8,
10, 14, 15, 18, 19 and 20) tested IgM-positive; further-
more, 5/23 patients (21.7%; patients 1, 2, 5, 12 and 17)
displayed weakly positive IgM values (Table 3). VP2-speciﬁc
IgG was observed in 11/23 patients with acute infection
(47.8%; patients 1–4, 16–21 and 23) and borderline results
were obtained in 2/23 patients (patients 13 and 23). In 8/
23 patients (34.8%), IgG was detected in combination with
IgM at positive or borderline values (patients 1, 2, 3, 8
and 7–20).
TABLE 2. Mean patient age in the groups studied
Patients
Mean age of all
patients (months)




Infectious diseases 57.4 22.5
Respiratory tract 40.5 22.1
Upper respiratory tract 48.3 20.6
Lower respiratory tract 20.1 18.7
Pneumonia 51.8 31.0
Gastrointestinal tract 68.5 20.6
Gastroenteritis 58.4 15.5





FIG. 1. Seroprevalence (a), median anti-
human bocavirus (HBoV) IgG titres (b) and
DNA prevalence (c) in children and adoles-
cents. The numbers given above the columns
representing the data obtained for various age
groups in (a) and (c) indicate the number of
individuals with positive results in relation to
that of all individuals tested. (Ru; relative
units).
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Discussion
HBoV genomes have been detected in respiratory tract sam-
ples of children worldwide mainly in retrospective analyses
[7,9,13,15,17]. Until recently, the serodiagnosis of HBoV
infection was not possible because of the lack of suitable
antigen preparations. Based on recombinant HBoV-like parti-
cles, HBoV-speciﬁc T-helper cell reactions have been
detected in adults [26]. Furthermore, an ELISA was estab-
lished that allowed the detection of HBoV-speciﬁc IgG and
IgM in 94% and 1% of adult healthy blood donors in Ger-
many, respectively [22]. These data point to the ubiquitous
prevalence of HBoV infection in the population and to a
seroconversion in childhood.
In the present study, we analyzed sera derived from 357
children and adolescents who presented with symptoms of
various infectious and non-infectious conditions for HBoV-
speciﬁc antibodies indicative of acute and past HBoV infec-
tion in combination with a PCR assay for the quantiﬁcation
of HBoV DNA. In this cohort, 88% of children aged
30–194 months displayed HBoV-speciﬁc IgG as a serological
marker for previous infection. This value is consistent with
previous data obtained in German and Japanese adults
[22,25] and indicates that the incidence of HBoV infection is
highest among young children. This assumption was conﬁr-
med when analyzing sera from children aged 10–30 months
using PCR: 16 out of a total of 23 DNA-positive patients
(69.6%) belonged to this age group. Because HBoV-speciﬁc
IgM was detected in almost 70% of the DNA-positive
patients, these individuals display the characteristic markers
for acute infections. In newborns and young children up to
the age of 9 months, HBoV DNA was detectable in only
three patients. This low incidence is probably a result of the
high prevalence of maternal IgG protective against acute
HBoV infection. Together with declining concentrations of
maternal IgG, a rising incidence of HBoV infection was
TABLE 3. Individual data of patients with acute human bocavirus (HBoV) infection





1 18/female Fever, rhinitis, cough Positive Weakly positive 102–103 –
2 22/female Acute laryngitis Positive Weakly positive 1.8 · 103 –
3 22/male Otitis media Positive Positive 1.6 · 103 –
4 4/male Acute bronchitis Negative Negative 1.0 · 102 RSV
5 12/male Bronchitis, otitis media Negative Weakly positive 1.9 · 105 –
6 12/male Bronchitis Negative Negative 3.1 · 105 –
7 17/male Spastic bronchitis Negative Positive 1.2 · 106 –
8 27/male Bronchitis Positive Positive 1.8 · 103 –
9 29/male Peribronchitis, otitis media Negative Negative 2.3 · 104 –
10 30/female (0a) Bronchitis Negative Weakly positive 1.9 · 105 –
30 (+2a) Bronchitis Negative Positive 1.1 · 105 –
30 (+3a) Bronchitis Negative Positive 4.6 · 103 –
11 15/female Bronchopneumonia Negative Negative 5.6 · 104 –
12 18/female Pneumonia, respiratory insufﬁciency Negative Weakly positive 2.2 · 105 –
13 29/female Bronchopneumonia Weakly positive Negative 102–103 –
14 42/female Pneumonia Negative Positive 1.0 · 103 Streptococcus A
15 51/female Atypical pneumonia Negative Positive 1.1 · 105 –
Group B
16 8/female Gastroenteritis Positive Negative 102–103 Rotavirus
17 12/male Gastroenteritis Positive Weakly positive 102–103 Rotavirus
18 13/male Gastroenteritis Positive Positive 102–103 Rotavirus
19 29/male Gastroenteritis, diarrhoea Positive Positive 3.3 · 103 –
20 41/male Inﬂammatory bowel disease Positive Positive 102–103 –
Non-infectious conditions
21 1/male Haematemesis Positive Negative 2.8 · 103 –
22 34/female Atonic seizure Weakly positive Negative 4.9 · 103 –
23 86/male Submanibular gland abscess Positive Negative 102–103 –
RSV: respiratory syncytial virus.
aFollow-up samples of patient 10 were taken 2 and 3 days after the ﬁrst sample, respectively.
TABLE 4. p-Values describing the signiﬁcance of acute HBoV
infection in patients (groups A and B) compared to patients








Respiratory tract disease p 0.00491 p 0.27165
Upper respiratory tract p 0.04357 p 0.96600
Lower respiratory tract p 0.00056 p 0.08776
Pneumonia p 0.00699 p 0.38904
Patients (group B)
Gastrointestinal tract disease p 0.01251 p 0.52407
Diarrhoea/nausea p 0.01434 p 0.57511
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observed. Children aged 31–36 months displayed high titres
of HBoV-speciﬁc IgG, with the titres declining in older age
groups (Fig. 1B). As the consequence of the increasing IgG
titres and seroprevalence, acute HBoV infections were rare
in children aged more than 30 months: only 4/217 (1.8%)
individuals showed markers of acute HBoV infection. These
data are consistent with those obtained from human parvovi-
rus B19 infections, with virus-speciﬁc IgG-titres peaking
directly after acute infection and declining afterwards [27,28].
With respect to distinct patient groups, we observed the
highest rate of acute HBoV infections in children with lower
respiratory tract disease and pneumonia. Compared to
patients with other infectious diseases (group C), this
enhanced rate of acute HBoV infection was highly signiﬁcant.
By contrast to other reports, co-infectious agents were only
observed in two HBoV DNA-positive patients: RSV infection
was diagnosed in a 4-month-old boy with acute bronchitis,
and a streptococcus A infection was evident in a girl suffering
from pneumonia (Table 3). This is particularly surprising
because RSV-infections were the main cause of bronchitis
and pneumonia in patients belonging to group A (data not
shown). The low rate of co-infections may be the result of
the present study the focusing on the exclusive analysis of
sera that were drawn at the time of patient admission to the
clinic. In the case of pathogens causing systemic infections
associated with respiratory tract disease, testing of sera for
the presence of virus and of antiviral immune reactions rep-
resents a more reliable diagnostic procedure compared to
the analysis of respiratory aspirates. The use of highly sensi-
tive PCR methods for the detection of viral and/or bacterial
nucleic acids in respiratory samples from hospitalized chil-
dren may yield positive results because of aerogenic contami-
nations or nosocomially transmitted co-infections. These are
frequent in paediatric wards, particularly during epidemic
phases of respiratory infections in winter and early spring.
As a member of the Parvoviridae, HBoV has to be considered
as an extremely stable pathogen resistant against disinfec-
tants and heat treatment [29, 31]. This property may facili-
tate nosocomial transmissions between children.
In addition to patients suffering from respiratory tract
illness, acute HBoV infection was observed in four young chil-
dren presenting with gastroenteritis (mean age 15.5 months),
in three of whom rotavirus co-infection was observed.
A recent study described the occurrence of HBoV in
stool samples of children with acute gastroenteritis [32].
Similar to our results, a high rate of rotavirus co-infections
was reported. Therefore, the possible role of HBoV as a
causative agent of acute gastroenteritis remains unclear.
Acute HBoV infection (IgM-/IgG-positive, DNA-positive)
was also observed in a boy presenting with an acute episode of
an underlying chronic inﬂammatory bowel disease. Markers
for acute HBoV infection were not observed in any of the chil-
dren presenting with symptoms of other infectious diseases
(group C). When analyzing children with non-infectious
diseases, low amounts of HBoV genomes were detectable
in three patients, although no symptoms for either respiratory
or gastrointestinal tract diseases were on record in any of
these cases.
Together with the high HBoV seroprevalence in older
children and adults, this observation indicates that HBoV
infections may be frequently asymptomatic or associated
with mild symptoms not requiring hospitalization.
In conclusion, the data obtained in the present study
reveal that acute HBoV infection is most frequent in young
children aged 10–30 months and that HBoV is as new infec-
tious agent in the growing group of pathogens causing respi-
ratory tract disease in young children.
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